Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter-defibrillator: The ADVANCE III trial

Joerg O. Schwab, Maurizio Gasparini, Maurizio Lunati, Alessandro Proclemer, Bernd Kaup, Elisabetta Santi, Guiseppe Ligorio, Catherine Klersy, João De Sousa, Andrzej Okreglicki, Angel Arenal, Maurits Wijffels, Bernd Lemke

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The purpose of this investigation is to evaluate whether a prolonged detection interval for life threatening ventricular tachyarrhythmia (VT) is able to reduce therapies (Rx) delivered by an implantable cardioverter-defibrillator (ICD). Until now, only the PREPARE trial demonstrated a reduction of ICD Rx in a cohort of primary prevention patients. Methods and Results: The ADVANCE III study is a prospective, randomized, parallel trial with 2 arms evaluating different intervals to detect (NID), i.e., 18-24 (as currently used) versus 30-40. The primary endpoint is to demonstrate a 20% reduction of ICD Rx (antitachycardia pacing or shocks) delivered to terminate spontaneous VT with a cycle length ≤320 ms in patients with Class I-IIA indication for ICD therapy, regardless of cardiac resynchronization capabilities. The worldwide investigation started in spring 2008 and is expected to be finished in 2011. Conclusions: The ADVANCE III trial is the first randomized investigation evaluating the reduction of ICD Rx for fast VT due to a prolongation of NID in a general ICD patient cohort. (J Cardiovasc Electrophysiol, Vol. 20, pp. 663-666, June 2009)

Original languageEnglish
Pages (from-to)663-666
Number of pages4
JournalJournal of Cardiovascular Electrophysiology
Volume20
Issue number6
DOIs
Publication statusPublished - Jun 2009

Keywords

  • Implantable cardioverter-defibrillator
  • Interval prolongation
  • Prospective randomized trial
  • Therapy detection
  • Ventricular tachyarrhythmia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter-defibrillator: The ADVANCE III trial'. Together they form a unique fingerprint.

Cite this